This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Dermatology
  • /
  • Tildrakizumab (MK-3222), an Anti- IL-23p19 Monoclo...

Tildrakizumab (MK-3222), an Anti- IL-23p19 Monoclonal Antibody, Improves Psoriasis in a Phase 2b Randomized Placebo- Controlled Trial

Read time: 1 mins
Published:15th Oct 2015
Author: Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG et al.
Availability: Free full text
Ref.:Br J Dermatol. 2015;173(4):930-9
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest